 |
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
May 10, 2012
|
9.6 KB |
|
| |
TARRYTOWN, N.Y., May 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012. The presentation is scheduled for 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time). The session may be accessed through the Company's...
|
|
Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
May 9, 2012
|
9.4 KB |
|
| |
TARRYTOWN, N.Y., May 9, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 11, 2012.
Conference call details are as follows: Live conference call (US): (888) 889-1309 Live conference call (Outside the US)...
|
|
Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
May 8, 2012
|
13.2 KB |
|
| |
TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against approval of ARCALYST® (rilonacept) Injection for Subcutaneous Use for the proposed indication for the prevention of gout flares in patient...
|
|
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
May 8, 2012
|
111.6 KB |
|
| |
TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., Ltd.（"Santen"）entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan. ...
|
|
Regeneron Reports First Quarter 2012 Financial and Operating Results
Apr 26, 2012
|
28.3 KB |
|
| |
TARRYTOWN, N.Y., April 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the first quarter of 2012 and provided an update on development programs.
The Company reported total revenues of $232 million in the first quarter of 2012, which include EYLEA net product sales ...
|
|
Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
Apr 12, 2012
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., April 12, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its first quarter 2012 financial and operating results on Thursday, April 26, 2012, before the U.S. financial markets open. The Company will host a conference call at 8:30 AM EDT that day.
Live audio of the conf...
|
|
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept)
Apr 5, 2012
|
18.2 KB |
|
| |
PARIS and TARRYTOWN, N.Y., April 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP® (aflibercept) concentrate...
|
|
Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Mar 26, 2012
|
21.9 KB |
|
| |
PARIS and TARRYTOWN, N.Y., March 26, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtil...
|
|
Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Mar 21, 2012
|
13.5 KB |
|
| |
TARRYTOWN, N.Y., March 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results of the Phase 1 clinical program with their investigational product REGN727/SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 ser...
|
|
Regeneron Announces Change in Date for Presentation at Barclays Capital 2012 Global Healthcare Conference
Mar 9, 2012
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., March 9, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13, 2012 at 3:45 p.m. Eastern Time. The March 13, 2012 date is a change from the previously announced date of March 14, 2012 and is due to conference resc...
|
|
Regeneron and Bayer Announce Approval of EYLEA® (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Mar 8, 2012
|
19.0 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, March 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA® (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related ...
|
|
Regeneron Announces March 2012 Investor Conference Presentations
Feb 28, 2012
|
9.4 KB |
|
| |
TARRYTOWN, N.Y., Feb. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Cowen and Company 32nd Annual Healthcare Conference at 10:40 a.m. Eastern Time on Tuesday, March 6, 2012
Barclays Capital 2012 Global Healthcare Conference at 3:45 ...
|
|
Regeneron Announces February 2012 Investor Conference Presentations
Feb 21, 2012
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Feb. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Citi 2012 Global Healthcare Conference at 3:00 p.m. Eastern Time on Tuesday, February 28, 2012
RBC Capital Markets' Healthcare Conference at 9:00 a.m. Eastern Time ...
|
|
Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Feb 13, 2012
|
9.6 KB |
|
| |
TARRYTOWN, N.Y., Feb. 13, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012. The presentation is scheduled for 9:00 a.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com,...
|
|
Regeneron Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
Feb 13, 2012
|
38.3 KB |
|
| |
TARRYTOWN, N.Y., Feb. 13, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.
The Company reported total revenues of $123.0 million for the fourth quarter and $445.8 million for the year ende...
|
|
Regeneron Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast
Feb 10, 2012
|
9.8 KB |
|
| |
TARRYTOWN, N.Y., Feb. 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2011 financial and operating results on Monday, February 13, 2012, before the U.S. financial markets open. The Company will host a conference call at 8:30 AM EST that day. The February 1...
|
|
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Jan 26, 2012
|
9.4 KB |
|
| |
TARRYTOWN, N.Y., Jan. 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2011 financial and operating results on Thursday, February 16, 2012, before the U.S. financial markets open. The Company will host a conference call at 8:30 AM EST that day.
Live...
|
|
Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference
Jan 3, 2012
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 30th Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2012. The presentation is scheduled for 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). The session may be accessed through the Company's web site, ...
|
|
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Jan 3, 2012
|
11.0 KB |
|
| |
TARRYTOWN, N.Y, Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company has entered into a non-exclusive license and partial settlement agreement (Agreement) with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) relating to U.S. ophthalmic sales of EYLEA™ (afliberce...
|
|
Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Jan 2, 2012
|
9.6 KB |
|
| |
TARRYTOWN, N.Y., Jan. 2, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. Eastern Time to provide an update on the status of the ongoing patent litigation with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY).
...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds